Pharma News

The emergence of drug-resistant bacteria is a global threat to human health, and the development of new antibiotics from scratch is an extremely expensive and time-consuming process. To address this urgent issue, researchers from Kent’s School of Biosciences have combined computational and microbiology laboratory approaches to identify existing drugs that can be repurposed to combat antibiotic-resistant bacterial infections.

The U.S. Food and Drug Administration approved Lenmeldy (atidarsagene autotemcel), the first FDA-approved gene therapy indicated for the treatment of children with pre-symptomatic late infantile, pre-symptomatic early juvenile or early symptomatic early juvenile metachromatic leukodystrophy (MLD).

The U.S. Food and Drug Administration approved Rezdiffra (resmetirom) for the treatment of adults with noncirrhotic non-alcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), to be used along with diet and exercise.

Taking study drugs like Adderall without a diagnosis is not only dangerous in itself, but can lead to other drug use and a decline in mental health, according to new research from Binghamton University.

A team of international researchers including experts from the University of Central Florida and Emory University has proven, for the first time in a field study, that using folic acid-fortified iodized table salt can prevent multiple severe birth defects.

AstraZeneca Pharma India Limited and Mankind Pharma Limited entered into an agreement for exclusive distribution of AstraZeneca's budesonide and formoterol fumarate dihydrate (inhaled corticosteroid (ICS) and long-acting beta-agonist (LABA) combination) brand Symbicort in India. AstraZeneca will retain the intellectual property rights to budesonide and formoterol fumarate dihydrate and will continue to be the Marketing Authorisation Holder (MAH) and import license.

DTAB was apprised that WHO Benchmarking is a process of assessment of National Regulatory Authority (NRA) based on Global Benchmarking Tools (GBT) done by team from WHO. Global Benchmarking of vaccine is the tool followed by WHO that involves the implementation of various regulatory functions at relevant institute of India including CDSCO as NRA.

By providing practical guidance on how to implement psychological interventions, this guide will help increase access to evidence-based interventions so that more people can benefit from them. The manual focuses on evidence-based psychological intervention manuals delivered by a non-specialist workforce.

Eli Lilly and Company announced results from a first-of-its-kind study of lebrikizumab specifically designed for people with skin of color and moderate-to-severe atopic dermatitis, commonly called eczema. In this study, treatment with lebrikizumab, an investigational medicine, showed improvement in skin clearance and itch relief. These late-breaking results from a Phase 3 study are being presented today at the American Academy of Dermatology (AAD) Annual Meeting.